Hemab Therapeutics Holdings Inc. Common Stock (COAG)
Stock · NASDAQ · Health Care
$30.07as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Resistance level
$43.17
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About COAG
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 cli…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 59
- Website
- ir.hemab.com
Fundamentals
- 1-day range
- $30.8$33.02
- Market cap
- $2.44B
- P/E (trailing)
- —
- P/E (forward)
- -12.15
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- -0.87
- Avg. volume
- 442.8K
52-week range
$23$55.42
Next earnings: November 16, 2026 · EPS estimate $-0.51
Forecasts
5 analyst ratings
Buy 91%
Hold 9%
Sell 0%
1-year price forecast
High
$65
+116.2%
Median
$60
+99.5%
Low
$58
+92.9%
Hemab Therapeutics Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- COAGHemab Therapeutics Holdings Inc. Common Stock$30.07▼ 7.53%Market cap $2.44BP/E —$23$55.42
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
- RVMDWRevolution Medicines Inc. Warrant$8.4▼ 13.98%Market cap $2.25BP/E —$0.2311$13.44
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COAG Hemab Therapeutics Holdings Inc. Common Stock | $2.44B | — | $30.07 | ▼ 7.53% | $23$55.42 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
| RVMDW Revolution Medicines Inc. Warrant | $2.25B | — | $8.4 | ▼ 13.98% | $0.2311$13.44 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →Acquired
295.5K
Disposed
32.7K
- RA Capital Healthcare Fund LP · June 16, 2026 · Buy61.5K @ $24.98
- RA Capital Healthcare Fund LP · June 15, 2026 · Buy6.1K @ $24.89
- RA Capital Healthcare Fund LP · May 20, 2026 · Buy996 @ $24.94
- RA Capital Healthcare Fund LP · May 19, 2026 · Buy3.8K @ $24.97
- RA Capital Healthcare Fund LP · May 12, 2026 · Buy6.4K @ $24.9
- RA Capital Healthcare Fund LP · May 11, 2026 · Buy25.7K @ $25
- RA Capital Healthcare Fund LP · May 11, 2026 · Buy14.1K @ $24.47
- RA Capital Healthcare Fund LP · May 8, 2026 · Buy1.5K @ $24.98
- RA Capital Healthcare Fund LP · May 7, 2026 · Buy2.0K @ $24.95
- RA Capital Healthcare Fund LP · May 7, 2026 · Buy7.9K @ $24.34
- RA Capital Healthcare Fund LP · May 6, 2026 · Buy53.4K @ $24.83
- RA Capital Healthcare Fund LP · May 6, 2026 · Buy14.6K @ $23.77
- RA Capital Healthcare Fund LP · May 5, 2026 · Buy10.3K @ $25
- RA Capital Healthcare Fund LP · May 5, 2026 · Buy87.1K @ $24.59
- Novo Holdings A/S · May 4, 2026 · Conversion32.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Rodman & Renshaw initiates coverage on Hemab Therapeutics
Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.
Rodman & Renshaw initiates coverage on Hemab Therapeutics. Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.